ELF4

Across TCGA pan-cancer cohorts, ELF4 Mutation is linked to patient survival in 10 of 34 cancer types, making it a survival-associated ELF4 data layer compared with 22 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher ELF4 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ELF4 expression acts as an unfavorable survival marker.

STAD, CESC, and PRAD are the cancer types where ELF4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	All	0.115	0.690	<.001	34	view →
CESC	DFS	Median	III,IV	0.091	0.728	<.001	24	view →
PRAD	OS	Median	All	0.540	0.990	<.001	12	view →
LIHC	OS	Median	All	0.193	0.690	.004	9	view →
SARC	DFS	Median	All	0.101	0.632	.011	6	view →
BLCA	OS	Median	III,IV	0.069	0.582	<.001	6	view →
LUAD	DFS	Median	All	0.253	0.815	<.001	6	view →
COAD	OS	Median	III,IV	0.159	0.692	.021	6	view →
LUSC	DFS	Median	All	0.275	0.662	.027	6	view →
SKCM	OS	Median	III,IV	0.245	0.721	.018	3	view →

Pink = unfavorable, green = favorable. Showing the 10 strongest of 10 lineages.

ELF4–STAD (OS)

Open the STAD breakdown →